News
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Devro Plc
Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab
Agilent Technologies Inc. (NYSE: A) today announced that it has become the first ‘Angel’ level sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: RPS Group plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
CI Financial Announces Debenture Financing to Refinance Existing Indebtedness
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) announced today that it has entered into an agreement to sell debentures with an aggregate principal amount of $400 million, maturing on December 2
BitNile Holdings Announces 2023 Revenue Guidance of More Than $200 Million
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced revenue guidance for 2023 of more than $200 million, including anticipated
Statement from State Street Corporation on Brown Brothers Harriman Investor Services Acquisition
State Street Corporation (NYSE: STT) today announced that it has mutually agreed with Brown Brothers Harriman & Co. (BBH) to terminate State Street’s proposed acquisition of BBH’s Investor Services
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
EQS-News: CPI PROPERTY GROUP – Completion of the Share Buy-back Offer
Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Hardman & Co Q&A on ICG Enterprise Trust: 1H’23 results – strong half year resilient outlook
EQS-News: ACCENTRO Increases Revenues – but Revises 2022 Forecast due to Challenging Market Environment
Custodian REIT plc : Disposal of business park office property for £2.8m
EQS-News: Eurobattery Minerals publishes Q3 report for 2022 – Significant mineral resource upside identified